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INTRODUCTION
The role of the immune system in the eradication of
residual leukemia after hematopoietic stem cell transplanta-
tion (HSCT) is well established. There is evidence that
removal of T-lymphocytes from the allogeneic graft to
reduce the risk of graft-versus-host disease (GVHD) is asso-
ciated with an increased incidence of recurrence of leukemia
after transplantation, whereas the occurrence of GVHD
correlates with decreased risk of relapse [1-10]. Attempts
have been made to enhance the antileukemic effect and
reduce the risk of GVHD. These attempts have had limited
success because the therapeutic window between the graft-
versus-leukemia (GVL) effect and GVHD is difficult to
deﬁne. Although allogeneic HSCT exhibits a stronger GVL
effect than does autologous bone marrow transplantation
(ABMT), detection of antileukemia-speciﬁc activity has also
been observed spontaneously post-ABMT [11,12]. Increas-
ing evidence indicates that at least one element of the cura-
tive potential of intensive chemotherapy is the patient
immune system. Patients can spontaneously develop immu-
nity to residual leukemia after chemotherapy; this immunity
can be induced and measured in vitro [13,14]. Therefore,
induction and expansion of autologous leukemia–specific
T-cells might lead to successful elimination of residual acute
myeloid leukemia (AML) without GVHD. These studies
imply that in allogeneic HSCT, ABMT, and chemotherapy,
immunological responses have key roles in the ultimate
eradication of residual leukemia cells.
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ABSTRACT
Evidence from allogeneic hematopoietic stem cell transplantation indicates a possible immune response against
leukemia-associated antigens in patients with either acute myeloid leukemia (AML) or chronic myeloid leukemia
(CML). However, autologous immune responses are less evident. We have developed a method using sequential
modulation of growth factors (SMGF) to generate specific anti-AML T-cells from primary cultures of mononuclear
cells (MNCs) from patients with AML. This culture method induces greater degrees of antigen presentation by
inducing dendritic cell (DC) differentiation of AML in the presence of autologous lymphocytes, which are then
expanded by interleukin (IL)-2 and costimulatory molecule ligation. MNCs consisting of 92.3% ± 5.1% AML blasts
and 3.4% ± 3.2% CD3+ T-cells were obtained from AML patients (n = 12) and cultured in AIM-V medium with IL-4
and recombinant granulocyte-monocyte colony-stimulating factor. Recombinant IL-2 was added on day 8. On day 21,
culture conditions were changed to anti-CD3/anti-CD28 monoclonal antibodies and IL-2. By day 42, 354 ± 182–fold
CD3+ T-cell expansion had occurred. Cytotoxic T-lymphocyte assays demonstrated that these T-cells caused significant
lysis of autologous leukemia cells and AML cell lines, but not of cells of other lineages, in an HLA class I–dependent
manner. Specific Vβ subgroups (Vβ3, -7, and -12a), possibly representing T-cell clones specific to AML-specific anti-
gens, were expanded in the cultures of cells from 3 AML patients. SMGF can be used to induce and expand autologous
T-cells with HLA class I–dependent antileukemia potential from the peripheral blood of AML patients. Adoptive
transfer of these expanded T-cells to patients is a possible therapeutic approach for further study. 
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Autologous cytotoxic effector cells can be activated and
expanded in untreated AML by high-dose interleukin (IL)-2
[15-18]. Bone marrow collected from newly diagnosed AML
patients was used to derive T-cell clones generated in IL-2–
containing media; these clones showed cytolytic activity
against autologous and allogeneic AML blast cells. Leukemic
blast cells were susceptible to autologous lymphokine-activated
killer (LAK) cells [19-22]. Passive immunotherapy with autol-
ogous LAK cells is an attractive treatment option, but to
eradicate residual leukemia, continued immunological mem-
ory in the form of induction and expansion of autologous
antileukemia–speciﬁc T-cells is required. Both cellular and
humoral immunity is suppressed in active AML. Immunosup-
pressive effects mediated by AML blasts may cause this effect.
AML blasts suppress host immune responses by release of
immunosuppressive soluble mediators such as transforming
growth factor β [23-25], soluble IL-2 receptors [26-28], and
soluble adhesion molecules [29-30]. AML blasts escape the
host immune attack by mechanisms such as decreased
expression of HLA and costimulatory molecules and down-
regulation of CD3 [31-33]. These mechanisms lead to failure
of antigen presentation and failure of immune response
against AML blasts. Because of the immunosuppressive effects
and the overwhelming growth of AML blasts, only small num-
bers of immunocompetent cells are present in AML patients
before treatment. It is widely accepted that immunotherapy
of AML will probably work best in a minimal residual dis-
ease setting after chemotherapy. Although chemotherapy
eradicates most AML blasts, it also eradicates the few and
potentially important AML-speciﬁc immunocompetent cells
present at diagnosis. Our hypothesis is that just as T-cell
depletion in allogeneic BMT increases the risk of relapse,
chemotherapy-mediated depletion of immunocompetent
T-cells may abrogate their potential beneﬁcial effects.
Dendritic cells (DCs) that have been obtained from
patients in complete remission (CR) and pulsed with
leukemia-derived peptides or cell lysates have been used to
obtain leukemia-speciﬁc T-cell effectors [34-36]. However,
in many situations, the tumor antigen(s) are unknown or
impossible to isolate. To avoid the need to identify and iso-
late leukemia-speciﬁc or -associated immunogenic peptides,
cytokines have been used to induce DC differentiation from
AML blasts. A DC phenotype with increased B7 expression
can be induced after in vitro exposure of native AML blasts
to several cytokine combinations. Such phenotypically
altered AML cells appear to be more efficient than native
blasts as antigen-presenting cells for the presentation of
leukemia-restricted peptides to T-cells. AML DCs can be
used to induce and activate leukemia-specific T-cells from
allogeneic peripheral blood mononuclear cells (PBMCs)
obtained from healthy bone marrow donors or autologous
PBMCs obtained from patients with AML in CR [37-45].
In this study, we investigated whether T-cells with anti-
AML specificity can be expanded from the PB of AML
patients with active disease. We reasoned that the blood of a
patient at presentation would contain all of the elements
necessary to elicit an immune response. Therefore, we
designed a tissue culture protocol involving sequential mod-
ulation of growth factors (SMGF) to induce DC differentia-
tion of AML blasts and subsequent antigen-speciﬁc T-cell
proliferation.
MATERIAL AND METHODS
Patient Samples
PB samples were collected from patients who had given
informed consent for diagnostic tests under the auspices of
the institutional review board of the UCSD Medical Center.
After Ficoll-Hypaque–gradient centrifugation, the mononu-
clear cells separated from patient blood were collected,
washed, and cultured or cryopreserved immediately.
Cells 
The HL60, U937, KG1a myeloid leukemia; Daudi,
RPMI-8866 lymphoma; H345 breast cancer; and DMS273,
H69 small cell lung cancer cell lines were obtained from
American Type Culture Collection (ATCC, Rockville, MD).
NB4 cells, which carry a 15:17 chromosomal translocation,
were kindly provided by Dr. M. Lanotte [46]. Cell lines
were cultured in RPMI-1640 containing 10% fetal bovine
serum (Hazelton Dutchland, Danver, PA) in a humidified
atmosphere of 5% CO2. Cells in log phase were freshly har-
vested from culture, washed 3 times, and resuspended in
RPMI-1640 before use.
SMGF Culture of AML PBMCs
Primary AML patient mononuclear cells isolated from PB
were suspended in culture medium (AIM-V medium [Gibco
BRL, Gaithersberg, MD] containing 10% human AB serum)
or culture medium supplemented with IL-4 (1000 U/mL)
(kindly provided by Schering-Plough Research Institute,
Kenilworth, NJ) and granulocyte-macrophage colony-
stimulating factor (GM-CSF) (50 ng/mL) (Immunex, Seat-
tle, WA) at a concentration of 4 × 106 cells/mL and cultured
in 6-well culture plates (Corning, Corning, NY). Every 4 to
5 days half of the culture medium was removed and the
remaining medium supplemented with fresh medium con-
taining growth factors. IL-2 (20 U/mL) (Collaborative
Research, Bedford, MA) was added to the culture at day 8. At
day 21, IL-2; anti-CD3 monoclonal antibody (MoAb), 10
ng/mL (clone: HIT3a, mouse immunoglobulin [Ig]G2a; BD
PharMingen, San Diego, CA); and anti-CD28 MoAb,
5 µg/mL (clone: CD28.2; BD PharMingen) were added with
fresh medium. The culture was continued for another 1 to
3 weeks with addition of fresh medium with IL-2/anti-
CD3/anti-CD28 every 4 to 5 days. Viable cell numbers in
the cultures were measured weekly by trypan blue exclusion.
For some experiments, the T-cells were further cultured in
medium containing IL-2 (20 U/mL) and 5% irradiated cry-
opreserved autologous AML DCs (AML PBMCs cultured
for 8 days with IL-4/GM-CSF) for 1 to 3 weeks before cyto-
toxic T-lymphocyte (CTL) assay.
Flow Cytometry Analysis
The immunophenotypes of primary AML PBMCs were
determined using ﬂow cytometry. CD1a, CD2, CD3, CD4,
CD5, CD7, CD8, CD10, CD13, CD14, CD15, CD16,
CD19, CD20, CD33, CD34, CD40, CD54, CD64, CD80,
CD86, CD83, CD95, HLA-DR, and TdT expression were
analyzed. For determination of DC differentiation of AML
blasts, cells were stained with CD3, CD4, CD8, CD14,
CD16, CD33, CD34, CD40, CD64, CD80, CD86, CD83,
and HLA-DR at day 8 of culture. To evaluate T-cell prim-
ing and proliferation, CD3, CD4, CD8, CD16, CD33, and
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CD56 expression were examined weekly after day 14 to the
end of culture. MoAbs were purchased from Becton Dickin-
son (San Jose, CA).
Morphology Study
The morphologic change of AML cells in the cultures
was examined with a phase-contrast transmission micro-
scope at days 4 and 8. The cytospin slides of AML cells
from day 8 of SMGF culture were stained with Wright-
Giemsa for microscopic examination.
Cytotoxicity Assays
The cytotoxic effects against autologous AML blasts,
AML cell lines, lymphoma cell lines, breast cancer cell lines,
and lung cancer cell lines of AML T-cells obtained from
SMGF culture were analyzed in standard 4-hour 51Cr
release assays (New England Nuclear, Boston, MA) as previ-
ously described [47]. T-cells used as cytotoxic effectors were
obtained from SMGF culture and serially diluted (in 3 repli-
cate wells) in 96-well plates. Target cells were incubated for
120 minutes at 37(C with 51Cr at 100 µCi/2 × 106 cells. The
cells were washed 3 times, and 5 × 103 cells were added to
each well. There were 6 wells containing only target cells
(spontaneous-release control) and 6 wells containing target
cells with 0.1 mL of 5% Triton X-100 (maximum-release
control). The plates were incubated at 37(C in a 5% CO2
humidiﬁed atmosphere for 4 hours, then samples were har-
vested and counted on 1450 MicroBeta TriLux (Wallac,
Turku, Finland). The percentage of speciﬁc lysis was deter-
mined by the formula:
(Experimental mean cpm – spontaneous release mean cpm)
(Maximum release mean cpm – spontaneous release mean cpm)
× 100
For the CTL blocking study, CTL analysis was per-
formed after 51Cr-labeled target cells were incubated with
100 µg/mL of 251 (anti-CD33, mouse IgG1) (Medarex,
Princeton, NJ), PM81 (anti-CD15, mouse IgM) (Medarex),
and W6/32 (anti-HLA class I, 1:100 diluted ascites, mouse
IgG2a) for 30 minutes at room temperature.
Colony-Forming Cell Assay 
Leukemia colony-forming cell (CFC) assay was per-
formed as previously described [48]. Briefly, AML T-cells
obtained from SMGF culture were serially diluted in
3 replicates in 96-well plates and mixed with HL60, NB4,
U937 cells (5000 cell/well) in a ﬁnal volume of 200 µL of
RPMI-1640 culture medium supplemented with 10% fetal
calf serum in 96-well U-bottom plates. The plates were
incubated for 2 hours (AML cell lines) at 37C in 5% CO2.
The cells in each well of AML cell lines were then sus-
pended, mixed with 0.9 mL MethoCult H4230 (StemCell
Technologies, Vancouver, BC, Canada) and 100 µL of con-
ditioned medium of the respective cell line, and seeded into
35 mm culture dishes. Cultures were maintained for 7 days
in a humidified atmosphere of 5% CO2, and an inverted
microscope was used to score cultures for leukemia cell
colonies containing 50 or more cells.
T-Cell Receptor Vβ Gene Repertoire Analysis
The anchored reverse transcriptase polymerase chain
reaction (RT-PCR) enzyme-linked immunosorbent assay
(ELISA) technique [49,50] was used to determine the per-
cent expression of each Vβ subgroup in the T-cell popula-
tions pre- and post-SMGF culture. Total RNA was extracted
from 5 × 107 AML PBMCs or 5 × 106 T-cells of SMGF cul-
ture with the RNeasy Kit (Quiagen, Valencia, CA). First-
strand complementary DNA (cDNA) was synthesized using
5 µg of the total RNA, an oligo-dT primer, and Superscript
RT (Gibco BRL) as described [49,50]. The puriﬁed cDNA
was poly-dG tailed using dGTP and terminal deoxytrans-
ferase (Boehringer Mannheim, Indianapolis, IN) and puriﬁed
using QIAquik puriﬁcation columns (Qiagen). One fourth of
the sample was subjected to primary anchored PCR ampliﬁ-
cation using an antisense oligonucleotide primer speciﬁc for
the constant region of T-cell receptor (TCR) (Ca) and a 9:1
mixture of 2 anchor sense-strand primers. The PCR prod-
ucts were puriﬁed using the QIAquik puriﬁcation columns,
and one third of this product was used as a template for a
nested PCR. This second PCR reaction was the same as
the primary anchored (AN) PCR except a 5′ biotinylated
Ca-antisense primer was used that was upstream of the initial
Ca primer. The nested PCR product was purified using
QIAquik puriﬁcation columns and distributed onto ELISA
wells that had been precoated with streptavidin (Sigma, St.
Louis, MO). Oligonucleotides corresponding to the 32-Vβ
[51] or 24-Vβ [49] subgroup–speciﬁc sense-strand sequences
were labeled with digoxigenin and terminal deoxytransferase
(Boehringer Mannheim). The captured double-stranded
PCR products were denatured with 0.1N NaOH and, after
washing, were hybridized with each of the digoxigenin-
labeled TCR Vβ oligonucleotide probes. The bound probes
were detected with peroxidase-conjugated antidigoxigenin
antibody (Boehringer Mannheim, Mannheim, Germany) and
its substrate 3,3′,5,5′-tetramethylbenzidine peroxidase
(Kirkegaard & Perry Laboratories, Gaithersburg, MD). The
reaction was stopped with 1M O-phosphoric acid (Fisher
Scientific, Pittsburgh, PA). The optical density (OD) at
450 nm was determined using an ELISA microplate reader
(Molecular Devices, Menlo Park, CA). The relative expres-
sion of each subgroup was calculated by dividing the OD
reading of each subgroup by the sum of the OD readings of
all subgroups times 100.
Statistical Analysis 
The significance level was determined by the Student
t test when applicable.
RESULTS
SMGF Culture for DC Differentiation of AML Blasts
Our hypothesis was that the SMGF protocol would
induce DC differentiation of AML blasts and activate the
T-cells in AML PBMCs with IL-4/GM-CSF in the first
stage (days 0-8) and induce AML-specific T-cells with
IL-4/GM-CSF and low-dose IL-2 in the second stage
(days 8-21). In the third stage, we expected to observe acti-
vation and expansion of AML-specific T-cells with IL-2/
anti-CD3/ anti-CD28 (days 21-35).
We studied 12 primary AML patient samples using
SMGF. The clinical characteristics of the patients and the
AML cell phenotypes before SMGF culture are shown in
Table 1. PBMCs from AML patients at ﬁrst presentation or
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relapse were obtained and immunophenotyped. The cells
consisted of 92.3% ± 5.1% CD33+ or CD34+ AML blasts
(range, 80.7%-98.7%) and 3.4% ± 3.2% CD3+ T-cells (range,
0.8%-13%). Unfractionated PBMCs were cultured in AIM-V
medium supplemented with IL-4 and GM-CSF to induce
DC differentiation of AML blasts. Cells cultured in medium
alone were used as controls. After 8 days, the expression of
CD64 on AML blasts cultured in GM-CSF/IL-4 was down-
regulated and HLA-DR, CD80, and CD86 were up-regulated;
a substantial proportion of cells (60%-70%) showed DC
morphology (Figure 1). Figure 2 shows the ﬂow cytometry
results for cells from 1 AML subject (patient 4), showing up-
regulation of CD80, CD86, and HLA-Dr expression on
AML cells. The geometric mean (±SD) of mean ﬂuorescence
intensity from 11 AML PBMCs after 8 days of culture with
GM-CSF/IL-4 (Figure 2) is signiﬁcantly up-regulated. How-
ever, AML PBMCs cultured with medium alone showed no
signiﬁcant changes (data not shown).
SMGF Culture for Generation of T-Cells
Fresh medium with GM-CSF/IL-4 and IL-2 (20 U/mL)
was added at day 8. At 21 days, flow cytometric analysis
results showed the proportion of CD3+ cells was increased
variably from 7% to 72%. Cells with DC morphology were
alive and well in the SMGF cultures. IL-2, anti-CD3, and
CD28 MoAb were added with fresh medium at 21 days.
Accelerated CD33+ AML blast decrease and CD3+ T-cell
increase was observed. Pure T-cells in the culture were
obtained within 2 to 3 weeks. According to ﬂow cytometric
analysis results, 99.5% ± 0.4% of the cells were CD3+,
CD16–, CD56– T-cells with 40.6% ± 22.9% CD4+ cells and
57.8% ± 22.8% CD8+ cells. The changes in the cell popula-
tions of 1 representative patient (patient 1) for 12 experiments
(expressed as the percentage of different cell phenotypes dur-
ing SMGF culture) is shown in Figure 3.
Results from 12 experiments showed that the duration of
culture needed to generate more than 99% T-cells in SMGF
culture differed among samples from different AML patients,
ranging from 21 days to 42 days (average, 31.3 ± 6.1 days).
Figure 4 summarizes patterns of T-cell development in
SMGF culture. The average percentage of CD4+ T-cells
increased faster than that of CD8+ T-cells in the ﬁrst and sec-
ond phases. Average percentages were 1.5% ± 1.5% CD4+
versus 2.1% ± 1.9% CD8+ T-cells on day 0, 4.0 ± 4.2% CD4+
versus 2.7% ± 2.8% CD8+ T-cells on day 8, and 17.1% ± 17%
CD4+ versus 11.5% ± 7.7% CD8+ T-cells on day 21. CD8+ T-
cell proliferation was then accelerated in the third phase, with
an average percentage of 57.8% ± 22.8% CD8+ versus 40.6%
± 22.9% CD4+ T-cells when more than 99% of T-cells were
obtained in the culture at an average of 31 days. These results
suggest the enhancement effect of IL-2 and IL-4 on activation
and proliferation of CD4 T-cells in the first and second
phases; these T-cells then contributed to the development of
cytotoxic T-cells by providing a priming signal to the AML
antigen-presenting cells. The data of the ﬁrst 6 experiments
indicated that at day 42, CD3+ T-cell expansion was 354 ± 182
times, CD4+ T-cell expansion was 445 ± 505 times, and CD8+
T-cell expansion was 228 ± 258 times. The T-cells in SMGF
culture could be continuously expanded beyond 60 days by
changing medium and re-adding IL-2/anti-CD3/anti-CD28.
Based on the magnitude of T-cell expansion observed by day
Table 1. Characteristics of AML Patients
Patient No. Age, y Sex FAB Subtype CD33+, % CD34+, % CD3+, % CD4+, % CD8+, %
Patient 1 30 F M5 96 0.1 2.1 0.1 2.0
Patient 2 33 M M2 86 0.3 13 5.2 7.5
Patient 3 68 F M5 95 0.1 2.4 2.4 1.0
Patient 4 57 M M5 99 0.2 0.8 0.4 0.4
Patient 5 65 M M7 12 92.0 3.4 3.0 2.8
Patient 6 68 M M2 2 91.6 2.5 0.8 2.1
Patient 7 29 M M4 94 57.5 2.6 1 1
Patient 8 73 M M1 53 87.6 2 1.8 0.9
Patient 9 75 M M5 98 0.1 2.4 0.3 1.0
Patient 10 49 F M4 91 0.5 3.2 2.2 0.6 
Patient 11 60 M M5 97 10.9 2.2 1 0.8
Patient 12 62 M M1 81 73.6 2.2 0.1 2.3 
Mean ± SD 75.2 ± 32.9 34.6 ± 39.9 3.4 ± 3.2 1.5 ± 1.5 2.0 ± 1.9
92.3 ± 5.1*
*Mean ± SD of the major cell populations of CD33+ or CD34+.
Figure 1. Morphology of AML cells cultured in GM-CSF/IL-4.
Wright-Giemsa staining of cytospin slides showed AML cells with den-
dritic morphology after 8 to 10 days.
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42, an estimated total of 109 CD8+ T-cells could be obtained
from 10 mL peripheral blood of a patient presenting with a
white blood cell count of 50,000/µL consisting of 1% T-cells.
Cytotoxicity of T-Cells Obtained Using SMGF Culture
of AML Cells
T-cells obtained from 10 of 12 SMGF cultures of AML
PBMCs showed similar cytotoxic effects (Table 2). In two cul-
tures, insufﬁcient cells were available for cytotoxicity assasys.
Standard 4-hour 51Cr-release assays demonstrated that the T-
cells induced and expanded from primary AML patients by
SMGF culture with GM-CSF/IL-4 caused signiﬁcant lysis of
autologous leukemia cells and AML cell lines HL-60 (Figure
5), NB4, and U937 (Table 2). There were no signiﬁcant cyto-
toxic effects on the cell lines of lymphoma (Daudi, RPMI-
8866), breast cancer (H345), small cell lung cancer (DMS273)
(Figure 5), AML (KG1a), lung cancer (H69), natural killer
cell–sensitive K562 cells, or Epstein-Barr virus immortalized
lymphocytoid cell lines (EBV-LCL) (data not shown).
Cultures were set up with cells from selected AML
patients to compare unmanipulated AML cells with AML
DCs that were induced in SMGF culture because of their
ability to stimulate autologous T-cells. Three culture meth-
ods were used: group 1, culture medium only; group 2, IL-2/
anti-CD3 added at the beginning of the culture and IL-2/
anti-CD3/anti-28 added when T-cells reached 90% of total
cultured cells; and group 3, 3-step SMGF culture. In groups
2 and 3, addition of anti-CD3/anti-CD28 to the culture was
stopped after 100% T-cells were obtained. T-cell cultures
were maintained with culture medium supplemented with
IL-2 (20 U/mL) and 10% irradiated autologous AML DCs.
In group 2, AML blasts were not induced to differentiate
into DCs and no anti-CD28 was added in the early phase of
the culture to block costimulation of B-7 by AML blasts, so
these AML blasts were expected to be able to function as
unmanipulated AML cell controls to stimulate autologous T-
cells. Group 2 cultured cells were also used to analyze
whether the CTLs that existed de novo were in an anergic
state and were activated by the anti-CD3/anti-CD28 MoAb.
No T-cells grew in group 1. Groups 2 and 3 both obtained
pure T-cell cultures in 4 of 4 experiments. For group 3, cul-
tures in 4 of 4 experiments maintained high CTL activity
Figure 2. Induction of costimulatory molecules CD80, CD86, and HLA-DR on AML blasts cultured in the presence of GM-CSF and IL-4. Pri-
mary AML PBMCs were cultured in AIM-V medium supplemented with GM-CSF/IL-4. CD80, CD86, and HLA-DR expression were analyzed by
ﬂow cytometry. Mean ﬂuorescence intensity (MFI) changes preculture (gray peak) and on day 8 (black peak) of culture of 1 representative experi-
ment is shown. The average MFIs from 11 AML PBMCs are listed below the ﬁgure.
Figure 3. Loss of CD33+ cells and gain of CD3+ (predominately CD8+) T-cells during culture in sequentially modulated growth factors. Cells from
primary AML patients were cultured in 3-phase SMGF cultures, including DC differentiation induction of AML blasts with GM-CSF/IL-4, T-cell
priming with GM-CSF/IL-4/IL-2, and T-cell expansion with IL-2/anti-CD3/anti-CD28. The changes in the cell populations of cells from 1 repre-
sentative of 12 experiments (patient 1) are expressed as the percentage of different cell phenotypes during SMGF culture.
R.-K. Zhong et al.
562
3 weeks after anti-CD3/anti-CD28 depletion. However, in
3 of 4 experiments, group 2 cultures lost CTL activity
3 weeks after anti-CD3/anti-CD28 depletion. Figure 6
shows the results from 1 of 4 experiments. These data sug-
gest that IL-2/anti-CD3/anti-CD28 added at the beginning
of the AML PBMC culture can also lead to pure T-cell cul-
tures and that these T-cells can exert an immediate killing
effect on AML cells. Because these T-cells lost killing activity
3 weeks after anti-CD3/anti-CD28 depletion, this killing
effect was most probably anti-CD3 MoAb activated and
mediated. These data indicate that DC induction of AML
blasts is important to prime AML-speciﬁc CTLs, that there
may be de novo AML-speciﬁc CTLs in a small number of
primary AML PBMCs, and that AML-speciﬁc CTLs can be
expanded by IL-2/anti-CD3/anti-CD28.
To study the speciﬁcity of the cytolytic T-cell reaction,
we performed experiments with blocking MoAb. Results of
6 experiments showed that the anti-HLA class-I MoAb
W6/32, but not PM81 (anti-CD15) or 251 (anti-CD33),
totally blocked the cytotoxic effect of AML T-cells in
SMGF, suggesting that the leukemia-specific cytotoxicity
was major histocompatibility complex (MHC) class I depen-
dent and cytotoxic T-cell mediated (Figure 7). Human
serum IgG (1 mg/mL) and mouse IgG2a (100 µg/mL) did
not block the cytotoxicity (data not shown).
To rule out the possibility that residual mouse anti-CD3
MoAb redirected killing of AML cells through CD64, we
further cultured T-cells obtained from the 3-group culture
for 3 weeks without anti-CD3/anti-CD28 MoAb. CTL
assay (Figure 8) demonstrated that AML T-cells obtained by
SMGF culture maintained strong cytotoxic activity against
AML cells after 3 weeks of culture without anti-CD3/anti-
CD28 MoAb. This cytotoxic effect could be totally blocked
by anti-HLA class-I MoAb W6/32. However, AML T-cells
obtained by anti-CD3/IL-2 culture lost cytotoxic activity
against AML cells after 3 weeks of culture without anti-
CD3 MoAb. Anti-CD3 MoAb (10 ng/mL) could reestablish
the cytotoxicity of these T-cells. As expected, the anti-CD3
MoAb–directed cytolysis of AML cells was only partially
blocked by anti–class I HLA MoAb W6/32.
Leukemia Colony-Forming Cell Depletion
The cytotoxic effect of AML cells on leukemia colony-
forming cells (L-CFCs) was analyzed by colony assay. AML
T-cells obtained from patient 6 were incubated with
Figure 4. T-cell development in SMGF culture. CD4+ and CD8+ T-cell
proliferation from day 0 to the day on which more than 99% of T-cells
were gained in SMGF cultures are shown. Day 0, 1.5% ± 1.5% CD4+
versus 2.1% ± 1.9% CD8+ T-cells; day 8, 4.0% ± 4.2v CD4+ versus
2.7% ± 2.8% CD8+ T-cells; day 21, 23.4% ± 20.3% CD4+ versus
16.7% ± 12.8% CD8+ T-cells; day 31, 40.6% ± 22.9% of CD4 versus
57.8% ± 22.8% CD8+ T-cells (data from 12 experiments).
Table 2. HLA Class I Phenotype of AML Patients and AML Cell Lines*
HLA Class I Phenotype Specific Lysis by AML T-Cells† against
Patients A B Cw Auto-AML HL-60 NB4 U-937
Patient 1 25, 31 18, 48 4, – 24 37 ND ND
Patient 2 2, 31 35, 51 4, – 10 44 38 48
Patient 3 3, 24 7, 62 3, 7 11 27 38 45
Patient 4 2, 28 8, 44 5, 7 20 22 16 23
Patient 6 1, 2 7, 8 7, – 51‡ 52 49 59
Patient 7 ND ND ND 40 52 43 ND
Patient 8 ND ND ND 25 54 ND 53
Patient 9 ND ND ND 48 56 56 54
Patient 10 ND ND ND 57 48 ND 57
Patient 11 ND ND ND 13 24 ND 23
Cell lines§
HL-60 1 B57, Bw4 6
NB4 11, 35 60, w6 4, 3
U-937 3, w19 5, 18 1, 3
*ND indicates not determined.
†E:T ratio, 20:1.
‡CTL from patient 6 against patient 4 AML cells. Other patients represent autologous CTL and AML samples.
§Cell lines HL60 and NB4 were HLA-typed using standard serological techniques at the UCSD Immunogenetics Laboratory. The HL60 typ-
ing was conﬁrmed by molecular typing methods. The U937 HLA type is that reported in the literature [53].
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5000 cells/well of HL-60, NB4, or U937 cells in triplicate in
96-well round-bottom plates at different effector:target-cell
(E:T) ratios for 2 hours. The cells in each well were then
suspended and mixed with 0.9 mL MethoCult H4230 and
seeded into 35-mm culture dishes for colony assay. The
results showed that AML T-cells from SMGF culture were
very effective L-CFC killers. These T-cells were so toxic to
leukemia cells that most L-CFCs were depleted by AML
T-cells even at an E:T ratio of 1:1 with a 2-hour incubation
(Figure 9). These results may explain the accelerated elimi-
nation of AML cells in the third phase of SMGF culture.
Analysis of T-Cell Repertoire in AML Patient T-Cells
We compared the TCR Vβ repertoires expressed by the
T-cells of healthy individuals (n = 13) to those of the AML
patients (n = 3) pre- and post-SMGF culture (Figure 10). The
preculture T-cells of each AML patient were found to have a
TCR Vβ repertoire that was unique and aberrant compared
to that found in preculture T-cells of healthy individuals. The
TCR subgroups Vβ5b, -5c, and -19 were most highly repre-
sented in patient 2; the subgroups Vβ5b, -5c, -6Ba, and -10
were overexpressed in patient 4. We observed an overexpres-
sion of Vβ5b and -5c by the T-cells of patient 6 compared to
the repertoire expressed by the T-cells of healthy individuals.
The expansion and reduction of the percentages of Vβ
subgroups from 3 patients after SMGF culture are shown in
Figure 11. If the specific Vβ subgroup was expanded, we
divided postculture % Vβ subgroup by preculture % Vβ sub-
group to obtain the multiple of expansion; if the speciﬁc Vβ
subgroup faded, we divided preculture % Vβ subgroup by
postculture % Vβ subgroup to obtain the magnitude of
reduction. The data clearly demonstrated the speciﬁc selec-
tion of certain clones and reductions in others in SMGF cul-
ture. Some clones, such as Vβ3 and Vβ12a, were commonly
expanded in 3 patient samples; some, such as Vβ6Ba, Vβ6bc,
Vβ7, and Vβ14, expanded in 2 of 3 samples; some expanded
individually. The extinguished clones acted the same. It is
possible that during culture some existing AML-speciﬁc CTL
clones expand, and some less-expressed clones are induced and
then expanded. Selected AML-reactive T-cells may recognize
more than one AML antigen or epitope simultaneously.
DISCUSSION
AML continues to be a difficult disease to cure. The
mainstay of therapy has been chemotherapy, including high-
dose chemotherapy with HSCT. Allogeneic HSCT is cura-
tive in a large proportion of patients, in part through a GVL
effect mediated by the donor immune system. This assertion
is supported by evidence from syngeneic HSCT, the associa-
tion of GVHD with durability of remissions following
allogeneic HSCT, and the efficacy of donor lymphocyte
infusions in inducing remissions in patients who relapse
after allogeneic HSCT.
The immune system in patients with AML has failed to
recognize and destroy the malignant cells. The reasons for
this failure are surely multiple and complex, and include: (1)
insufﬁcient antigen presentation by the malignant cells, (2)
Figure 5. CTL activity against AML cells (primary and HL60) and
lack of activity against nonmyeloid cancer cells. Standard 4-hour
51Cr-release assays used the T-cells obtained from SMGF culture of
AML-PBMCs (from patient 1) as effectors. Ten experiments
showed similar cytotoxic effects against autologous AML and AML
cell line cells without effects against various cell lines other than
AML cell lines.
Figure 6. Comparison of unmanipulated AML cells with AML DCs induced in SMGF culture for their ability to stimulate autologous T-cells (data
from 1 of 4 experiments). Left, group 2 (IL-2/anti-CD3 added at the beginning of the culture and IL-2/anti-CD3/anti-28 added when T-cells
reached 90% of total cultured cells). Right, group 3 (3-step SMGF culture).
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immune suppression by soluble or cellular factors, and (3)
insufficient numbers of specific lymphoid cells to react to
the rapidly growing clone of malignant cells. The existence
of leukemia-associated antigens is suggested by several lines
of evidence such as the GVL effect noted in HSCT [6], the
identification of specific antigens recognized by cytolytic
T-cell clones [10], and over-expression of certain gene prod-
ucts detected by microarray technology [52].
While investigating the possibility that T-cells with
anti-AML speciﬁcity can be expanded from the PB of AML
patients with active disease, we have developed a strategy of
3-stage sequential modulation of growth factors. The first
phase is initiation of AML blast differentiation to DCs, the
second phase is priming of T-cells, and the third stage is
expansion of T-cells.
We have shown that a DC phenotype with increased B7
and HLA-DR expression can be induced and up-regulated
after in vitro exposure of native AML blasts to cytokine
combinations of IL-4/GM-CSF. AML-speciﬁc CTLs can be
induced and expanded thereafter. Successful induction and
expansion of AML-specific T-cells from all 12 primary
AML patients with diseases of various French-American-
British (FAB) subtypes indicates the potential power of this
strategy in adoptive immunotherapy of AML.
Primary AML patient MNCs in 3-phase SMGF culture
produced expanded CTLs that caused significant lyses of
autologous leukemia cells and AML cell lines HL-60, NB4,
and U937 but had no effect on cell lines of AML (KG1a),
lymphoma (Daudi, RPMI-8866), EBV-LCL, breast cancer
(H345), natural killer cell–sensitive K562 cells, or small cell
lung cancer (DMS273). Anti–HLA class I MoAb W6/32
totally blocked the CTL effect. The T-cells obtained from
the SMGF culture were CD3+, either CD4+ or CD8+, and
CD16– or CD56–. These results indicate that the AML-
speciﬁc cytotoxic effect of AML T-cells was dependent on
recognition of MHC class I molecules and was not nonspe-
ciﬁc LAK cell activity.
Engagement of CD64 by the Fc portion of the anti-
CD3 MoAb (IgG2a subclass) is at least partially responsible
for T-cell activation, because the Fc portion of the MoAb
acts as a CD3 cross-linking agent. We explored the possibil-
ity that the anti-CD3 MoAb enhanced CTL activity by
mediating antibody-dependent cell-mediated cytotoxicity
(ADCC) because, although the level of anti-CD3 was in the
Figure 7. Blockade of CTL activity by MoAb to class I HLA. CTL assay results after 51Cr-labeled target cells were incubated with 50 µg/mL
MoAb PM81 (anti-CD15), 251 (anti-CD33), or MoAb W6/32 (anti-HLA class-I) (1:100 diluted ascites) for 30 minutes. Results of 1 representative
(cells from patient 4) of 6 experiments are shown.
Figure 8. The AML-speciﬁc cytotoxicity of T-cells from SMGF culture
is not anti-CD3 MoAb mediated. Group 2 and group 3 T-cells harvested
from AML PBMC cultures described in Figure 5 were cultured for
3 weeks with IL-2 and irradiated autologous AML DC and analyzed for
cytotoxicity against AML cells. A, Cytotoxicity against AML cells without
blocking antibody; B, blocking with anti–HLA class I MoAb W6/32; C,
incubation with anti-CD3 MoAb; D, incubation with anti-CD3 MoAb
and blocking with W6/32. Data are representative of 4 experiments.
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low nanomolar range, some of the killing might have been
due to ADCC. This hypothesis was negated, however, by
the finding that high concentrations of human IgG and
mouse IgG2a did not block the CTLs of AML T-cells.
Comparative study of AML-speciﬁc cytotoxicity of T-cells
from SMGF culture and T-cells from IL-2/anti-CD3 MoAb
added at the beginning of the culture further ruled out this
possibility. Although the addition of anti-CD3 MoAb could
redirect and enhance the killing of AML cells, this killing
could not be blocked by anti–HLA class I MoAb W6/32.
When T-cells were cultured without adding fresh MoAb for
more than 2 weeks, there was no detectable remaining cell-
bound MoAb, yet the T-cells still had demonstrable
cytolytic activity. This ﬁnding demonstrated that the T-cells
mediated lysis that was not ADCC. However, even higher
levels of killing could be achieved through the addition of
anti-CD3. The level of CD64 on AML cells may be impor-
tant to the potency of CTL generation through T-cell acti-
vation in the induction phase of the cultures.
The cytotoxicity was not MHC restricted, because pri-
mary AML patient cells, HL-60 cells, NB4 cells, and U937
cells do not share the same HLA phenotype (Table 2).
Although recognition of HLA class I molecules is essential
for cytotoxicity of AML-speciﬁc T-cells in SMGF culture,
strict HLA identity does not seem to be required. There was
no significant cytotoxicity against the myeloid cell line
KG1a (which is at a more primitive differentiation stage),
selected solid tumor cell lines, or nonmyeloid leukemia
lines. MHC-unrestricted killing of various tumor cells by
CTLs has been reported, including autologous and allo-
geneic CML cells (by bcr-abl–specific CD8+ CTLs) [54],
acute leukemia cells [55], breast and pancreatic cancer cells
(by MHC-unrestricted MUC-1–speciﬁc CTLs) [56-58], and
melanoma cells [59]. Human CD8+ T-cells raised in
response to herpes simplex virus (HSV) lysed autologous
and allogeneic HSV-infected target cells via a non–MHC-
restricted pathway [60]. In these studies, CTLs recognized
specific antigens because specific antigens were used to
induce the antigen-speciﬁc CTLs in a T-cell–priming sys-
tem. In our SMGF culture system, we obtained MHC-
dependent AML-speciﬁc CTLs directed to unknown target
antigens. The mechanism involved in the killing of AML
cells by these T-cells will require further study. It is possible
that distinct populations of CTLs that can kill autologous or
allogeneic AML cells or both may exist in the bulk cultures.
To investigate this possibility, we are attempting to clone
individual T-cell clones.
Figure 9. Effect of CTL on L-CLCs from 3 cell lines. AML T-cells
(from patient 6) of SMGF culture were incubated for 2 hours with
5000 cells/well of HL-60, NB4, and U937 cells in triplicate in 96-well
round bottom plates at different E:T ratios. L-CLC assay was per-
formed as described in “Material and Methods.”
Figure 10. Pre-SMGF culture TCR Vβ repertoires expressed by the T-cells of healthy individuals (n = 13) compared to those
of AML patients (Pt.) (n = 3).
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The results of TCR repertoire analysis suggest that
oligopeptide-speciﬁc cytotoxic T-cell clones against several
AML-associated or AML-specific antigens may be gener-
ated in these cultures. It is possible that unidentiﬁed AML
antigens can be isolated using the AML-specific CTLs of
the SMGF culture as a probe. We plan to study more
patients prospectively to further deﬁne the HLA and other
antigenic variables that operate in this system.
The TCR Vβ analysis revealed that speciﬁc T-cell sub-
groups were expanded by the SMGF culture conditions.
Specifically, the Vβ3 and -12a subgroups that were
expanded in the cultures of all 3 AML patients could repre-
sent T-cell clones that are expanded in response to AML-
speciﬁc antigens. T-cell proliferation by direct stimulation
of growth factors would result in a polyclonal TCR Vβ
repertoire as expressed preculture by the T-cells of the
3 AML patients. Selected expansion and extinction of spe-
ciﬁc Vβ subgroups post-SMGF culture suggests that AML
patients may have cytotoxic T-cell clones that specifically
recognize autologous leukemic cells.
The circulating T-cells of patients with chronic lympho-
cytic leukemia (CLL) have also been shown to exhibit
abnormal TCR Vβ repertoires [61-64]. The overexpressed
T-cell clones observed in these patients may also reﬂect an
ineffective response to leukemia-associated antigens. Results
have shown evidence for T-cell clonal expansion of speciﬁc
Vβ subgroups that are expressed by CD8+ T-cell clones that
recognize autologous tumor cells in vitro [61]. Similarly, our
studies suggest that the SMGF culture may result in expan-
sion of speciﬁc Vβ subgroups expressed by cytotoxic T-cell
clones that speciﬁcally recognize autologous leukemic cells.
In conclusion, we have demonstrated that HLA class
I–dependent AML-specific CTLs can be induced and/or
expanded from the PB of AML patients with active disease
by a 3-phase sequential modulation of growth factors. The
advantage of this approach to the generation of AML-reactive
CTLs is that no cell separation or purification is needed.
Rather, a sequential change in the combination of growth
factors during culture of primary AML cells for a period of
30-40 days results in the generation and expansion of
immunocompetent AML-specific cytotoxic T-cells. It may
be possible to adoptively transfer such expanded autologous
cells to patients in remission as immunotherapy to eradicate
residual disease following induction chemotherapy.
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Figure 11. The expansion index (EI) of the percentage of TCR Vβ subgroups of SMGF. The anchored RT-PCR ELISA technique of TCR reper-
toire analysis was performed using pre- and post-SMGF culture cells from 3 AML patients, patient 2, patient 4, and patient 6, as described in
“Material and Methods.” If the speciﬁc Vβ subgroup was expanded, then the postculture % Vβ subgroup was divided by the preculture % Vβ sub-
group to obtain the multiple of expansion (+EI). If the speciﬁc Vβ subgroup faded, the preculture % Vβ subgroup was divided by the postculture %
Vβ subgroup to obtain the magnitude of reduction (–EI).
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